<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379492</url>
  </required_header>
  <id_info>
    <org_study_id>20-187</org_study_id>
    <nct_id>NCT04379492</nct_id>
  </id_info>
  <brief_title>A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19</brief_title>
  <official_title>Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2
    infection. No pts have been enrolled.
  </why_stopped>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Actual">September 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical improvement is defined as a composite endpoint of a two-point clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI). The OSCI is an ordinal scale of 9 severity levels (from 0 to 8) for COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants requiring mechanical ventilation for respiratory failure</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical improvement is defined as no mechanical ventilation for respiratory failure attributed to SARS-CoV-2 within 14 days of randomization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19</condition>
  <condition>COVID19</condition>
  <condition>Sars-CoV2</condition>
  <condition>SARS-Cov-2</condition>
  <arm_group>
    <arm_group_label>Arm A - hydroxycholoroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.</description>
    <arm_group_label>Arm A - hydroxycholoroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.</description>
    <arm_group_label>Arm B - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older

          -  Subjects must have a documented positive test for the SARS-CoV-2 infection within 7
             days of randomization

          -  Subject must be hospitalized within 72 hours of randomization

          -  Subjects must be receiving standard of care for SARS-CoV-2

          -  Subject/Legally Authorized Representative (LAR) must have the ability to understand
             and give informed consent

          -  Subject must be able to take and absorb hydroxychloroquine at the discretion of the
             investigator

        Exclusion Criteria:

          -  Prior receipt of hydroxychloroquine for treatment or prophylaxis of SARS-CoV-2 or
             patient is taking hydroxychloroquine for other approved indications (e.g., lupus,
             rheumatoid arthritis)

          -  No documented SARS-CoV-2 infection

          -  Mechanical ventilation

          -  Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives
             Preexisting retinopathy documented in medical history

          -  Pregnancy or Breastfeeding

          -  Concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins
             (rifampin, rifabutin)

          -  Antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine,
             flecainide)

          -  History of glucose-6-phosphate dehydrogenase deficiency

          -  Pre-treatment corrected QT interval (QTc) &gt;500 milliseconds

          -  Pressor requirement to maintain blood pressure

          -  Alanine aminotransferase (ALT) and/or asparate aminotransferase (AST) level &gt; 5X upper
             limit of normal

          -  Creatinine clearance &lt;30 mL/min or requirement of dialysis or continuous venovenous
             hemofiltration

          -  Concomitant participation in a therapeutic trial for SARS-CoV-2 or receiving any
             experimental treatment for SARS-CoV-2 within 7 days of randomization

          -  Any condition that in the opinion of the principal investigator would prevent
             participation in the trial or would interfere with the trial endpoints
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genovefa Papanicolaou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-CoV2</keyword>
  <keyword>SARS-Cov-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>COVID19</keyword>
  <keyword>Hydroxycholoroquine</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>20-187</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

